Fadogia Agrestis
Fadogia agrestis is a West African shrub promoted as a natural testosterone booster. The evidence is limited to animal studies, and those same studies flagged dose-dependent testicular toxicity. No human clinical trials exist.
What Is Fadogia Agrestis?
Fadogia agrestis is a shrub native to Nigeria and other parts of West Africa, belonging to the Rubiaceae family. The stem is the part used traditionally — in Nigerian folk medicine it was employed as an aphrodisiac and general tonic. The plant contains alkaloids, saponins, anthraquinones, and flavonoids, though the specific active compounds responsible for hormonal effects have not been isolated or characterised.
Unlike well-studied botanicals such as ashwagandha or tongkat ali, fadogia agrestis has no monograph in any major pharmacopoeia (including the Indian Pharmacopoeia), no standardised extraction process, and no established quality control markers. What you buy as "fadogia agrestis" in a capsule may vary dramatically in composition between manufacturers — and there is no way for consumers to verify authenticity or potency.
It entered the global supplement market in the early 2020s, primarily after being recommended by neuroscientist Andrew Huberman on his podcast alongside tongkat ali as part of a testosterone-support stack. Before that, it was virtually unknown outside of ethnobotanical literature. Its rapid commercialisation outpaced any scientific validation — a pattern increasingly common in the supplement industry.
Mechanism — LH-Mimicking Activity
The proposed mechanism of action is based on a single rodent study (Yakubu et al., 2005). The aqueous stem extract appeared to increase serum testosterone in rats in a dose-dependent manner over 5 days. The hypothesised mechanism is luteinising hormone (LH)-mimicking activity — compounds in the extract may act directly on Leydig cells in the testes, stimulating testosterone production without going through the hypothalamic-pituitary axis.
In normal physiology, the pituitary gland releases LH, which binds to LH receptors on Leydig cells and triggers testosterone synthesis. If fadogia compounds mimic LH at the receptor level, this would bypass the brain's regulatory feedback loop entirely — a mechanism with significant implications for both efficacy and safety.
This distinction matters because LH-mimicking activity could theoretically:
- Stimulate testosterone production independently of the HPG (hypothalamic-pituitary-gonadal) axis
- Potentially suppress endogenous LH secretion via negative feedback — similar to how exogenous testosterone suppresses natural production
- Overstimulate Leydig cells in a way that the body's natural regulatory mechanisms cannot modulate
If this mechanism is real, it would be pharmacologically distinct from adaptogens like ashwagandha (which lower cortisol) or tongkat ali (which may reduce SHBG and support HPG axis signalling). However, the mechanism has not been confirmed in human tissue, the receptor binding has not been characterised, and the specific compounds responsible have not been identified or isolated.
The Safety Concern
This is the critical issue with fadogia agrestis that most supplement marketing omits. The same Yakubu et al. study that demonstrated testosterone increases also reported significant dose-dependent testicular toxicity in rats:
- Increased testicular weight at higher doses — a marker of oedema or abnormal cellular proliferation, not a positive sign
- Altered testicular histology — cellular damage visible under microscopy, including changes to seminiferous tubule architecture
- Elevated cholesterol and lipid changes in testicular tissue, suggesting disrupted cellular metabolism
- Dose-dependent organ toxicity — effects worsened at higher doses and longer durations
- No reversibility data — the studies did not assess whether the damage reversed after discontinuation
The fact that the testosterone increase and the testicular damage occurred in the same study, at the same doses, is a serious red flag. In pharmaceutical development, this toxicity-efficacy overlap would halt progression to human trials until the toxicity mechanism was fully understood and mitigated.
It is also worth noting that the rat studies used relatively short durations (5–28 days). Many supplement users take fadogia agrestis for months at a time — a duration for which there is zero safety data in any species. The long-term consequences of chronic use are entirely unknown.
There are zero published human safety or pharmacokinetic studies for fadogia agrestis. The only toxicology data comes from rat studies, which showed testicular damage at the same doses that increased testosterone.
If you choose to use this supplement, you are accepting an uncharacterised risk with no human data to guide safe dosing, maximum duration, or reversibility of potential harm. At minimum, run comprehensive bloodwork (testosterone, LH, FSH, liver enzymes, kidney function) before and during use, and discontinue at the first sign of adverse changes.
Evidence Quality
The evidence base for fadogia agrestis is among the weakest of any widely sold testosterone supplement. To be direct about where this stands on the evidence hierarchy:
- Zero human clinical trials — no RCTs, no open-label studies, no case series, no case reports
- Two to three rodent studies from a single Nigerian research group (Yakubu et al.) — these have not been independently replicated by any other laboratory
- No human pharmacokinetics — absorption, metabolism, half-life, and bioavailability in humans are completely unknown
- No standardised extract — unlike KSM-66 ashwagandha or LJ100 tongkat ali, there is no validated extraction process with guaranteed active compound content
- No dose-response data in humans — the "600–1,200 mg" range is an allometric scaling estimate, not a clinically derived dose
- Popularity driven by podcast endorsement, not by clinical evidence progression — this is an important distinction
In evidence-based medicine, animal data is considered preliminary. It generates hypotheses for human testing — it does not validate supplement use. Many compounds that show promise in rodent models fail or show different effects in humans. The failure rate from animal studies to successful human outcomes is estimated at over 90% in drug development.
Compare this to ashwagandha (20+ human RCTs) or tongkat ali (multiple human trials with testosterone endpoints). Fadogia agrestis is not in the same evidence category — it is several stages behind in the research pipeline.
The primary reference is Yakubu et al., 2005 on PubMed. If you are evaluating this supplement, reading the original study — including the toxicity findings — is strongly recommended before making a decision.
Dosing Context
Supplement brands typically sell fadogia agrestis at 600–1,200 mg per day of stem extract. This dosing is derived from traditional use estimates and the rat study doses (scaled by body weight), not from human dose-finding trials.
The rat studies used 18, 50, and 100 mg/kg body weight — the human-equivalent doses are rough approximations at best, calculated using standard allometric scaling factors that do not account for differences in metabolism, absorption, or tissue sensitivity between species.
- There is no established safe dose in humans
- There is no established effective dose in humans
- Cycling protocols (e.g. 8 weeks on, 4 weeks off) are entirely speculative — no data supports any specific cycle length or confirms that cycling mitigates toxicity risk
- Product quality varies enormously — without a standardised extract, what you receive may differ significantly between brands and batches
- Some products combine fadogia with tongkat ali; the interaction between these two compounds has never been studied in any species
- Third-party testing (e.g. for heavy metals, contaminants, and actual fadogia content) is essential if you choose to use this supplement
Biomarker Connections
If you are considering or currently taking fadogia agrestis, running bloodwork before and during use is not optional — it is the only way to detect whether the supplement is having any effect (positive or negative) on your hormonal and organ health.
The following biomarkers are relevant to monitor:
- Total testosterone — the primary claimed benefit; test at baseline and 8–12 weeks
- Free testosterone — more functionally relevant than total; should rise if the supplement works
- LH and FSH — if fadogia mimics LH, exogenous LH-like stimulation could suppress endogenous LH via feedback
- SHBG — sex hormone-binding globulin; determines how much testosterone is bioavailable
- DHEA-S — adrenal androgen precursor; helps differentiate adrenal vs gonadal testosterone sources
- Liver enzymes (ALT, AST) — prudent to monitor given the lack of human toxicology data
- Kidney function (creatinine, BUN) — another basic safety screen warranted by the absence of toxicology data
Run a full panel at baseline before starting, and retest at 8 and 12 weeks. If any markers move in a concerning direction — particularly LH suppression, liver enzyme elevation, or kidney function changes — discontinue immediately and consult a physician. Do not rely on subjective feelings of wellbeing as a proxy for safety.
Frequently Asked Questions
Does fadogia agrestis actually increase testosterone?
In rat studies, aqueous stem extract increased serum testosterone in a dose-dependent manner over 5 days. However, there are zero published human clinical trials confirming this effect. The testosterone claims circulating online are extrapolated entirely from rodent data, which does not reliably translate to humans. Many compounds that raise testosterone in rats have no effect — or different effects — in humans.
Is fadogia agrestis safe to take?
There is no human safety data whatsoever. The same rat studies that showed testosterone increases also showed dose-dependent testicular toxicity — including increased testicular weight, cellular damage, and altered histology. Without human pharmacokinetic or toxicology studies, the safety profile is genuinely unknown. The absence of reported adverse events online does not constitute evidence of safety — it reflects the absence of systematic monitoring.
Why is fadogia agrestis so popular despite weak evidence?
Fadogia agrestis gained mainstream popularity after Andrew Huberman recommended it on his podcast in 2021–2022. The supplement industry rapidly commercialised it globally. In India, where testosterone optimisation interest is growing fast among young men, it entered the market through international brands and local manufacturers. Its popularity is driven almost entirely by influencer endorsement rather than clinical evidence or traditional Indian medicinal use — fadogia is a West African plant with no history in Ayurveda or Siddha medicine.
What are safer alternatives to fadogia agrestis for testosterone?
Tongkat ali (Eurycoma longifolia) and ashwagandha (KSM-66) both have multiple human RCTs showing testosterone increases with established safety profiles. Tongkat ali at 200–400 mg/day has the strongest direct testosterone evidence among herbal supplements. Ashwagandha raises testosterone indirectly via cortisol reduction. Both have standardised extracts, known safety profiles, and years of human use data. For Indians looking to optimise testosterone naturally, these are the evidence-based starting points.
Bottom Line
Fadogia agrestis occupies a unique and cautionary position in the supplement world: widely sold, heavily promoted, and backed by essentially no human evidence. The animal data is intriguing but inseparable from the toxicity findings.
If you are serious about testosterone optimisation, start with compounds that have actual human trial data — tongkat ali and ashwagandha — and confirm your baseline hormonal status with bloodwork before adding any supplement. Optimising sleep, resistance training, body composition, and stress management will have a larger and more reliable impact on testosterone than any supplement.
If human safety trials for fadogia agrestis are eventually published, the risk-benefit calculus may change. Until then, the honest assessment is that you are experimenting on yourself with an uncharacterised compound. The supplement industry's ability to sell products ahead of evidence is not a reason to assume those products are safe or effective.